Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomised two parallel groups multicenter study using a Prospective Randomised Open Blinded End-point design (PROBE), aiming at comparing the efficacy of a therapeutic strategy targeting the normalisation of arterial stiffness for reducing cardiovascular (CV) and renal events, in comparison with a classical therapeutic strategy implementing the European Society of Hypertension-European Society of Cardiology (ESH-ESC) Guidelines, in patients with essential hypertension and medium-to-very high CV risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure

NCT00925470

Blood Pressure

COMPLETED

The Long-term Safety and Effect of Renal Denervation

NCT05818813

Hypertension

UNKNOWN

Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population

NCT00901355

Hypertension Elderly Cardiovascular Mortality +2 more

COMPLETED

Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension

NCT03511313

Primary Hypertension

UNKNOWN NA

Knowledge of Vascular Age Contributes to Improve the Collaboration Between Community Pharmacies and Primary Health Care Physicians in Reducing Blood Pressure in Hypertensive Patients.

NCT06761235

Hypertension and Cardiovascular Risk Factors

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective is to show that a therapeutic strategy targeting the implementation of international guidelines PLUS the normalisation of blood pression (BP \< 140 and 90 mmHg) plus the normalisation of arterial stiffness (measured every 6 months) Pulse Wave Velocity group (PWV group) reduces CV and renal events to a significantly greater extent than the sole implementation of Guidelines (conventional group, with PWV measurement at baseline and every 2 years).

Experimental design: Prospective Randomised Open Blinded Endpoint (PROBE) multicenter, two parallel groups, study.

Therapeutic strategy in the PWV group:

1. Use maximal recommended doses of angiotensin-converting-enzyme inhibitor (ACEIs) or Angiotensin II receptor blockers (ARBs) as first step treatment. And then adapt treatment to PWV values.
2. In second step, use combination therapy with Calcium channel blockers (CCBs)
3. Use diuretics in combination therapy, either as an alternative to CCBs in second step or as triple therapy in third step
4. Use, as fourth step, vasodilating beta-blockers (VD-BB) or spironolactone
5. In parallel, correct all CV risk factors according to ESH-ESC Guidelines, and reinforce treatment (hypolipidemic drugs, glucose lowering drugs, antiplatelets) if secondary prevention.

Therapeutic strategy in the conventional group: Apply the ESH-ESC Guidelines

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PWV group

Cardiovascular risk management based on PWV will include altogether

1. the implementation of international guidelines,
2. the normalisation of blood pressure, and
3. the normalisation of arterial stiffness

Group Type ACTIVE_COMPARATOR

Cardiovascular risk management based on PWV

Intervention Type OTHER

Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).

1. In the "PWV group", PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.
2. In the "conventional group", PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician

Conventional group

These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiovascular risk management based on PWV

Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).

1. In the "PWV group", PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.
2. In the "conventional group", PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* registration to the French social security system
* patients who did not specifically express their non willingness to participate

PLUS either A, B or C:

1. Patients with essential hypertension, aged 55 to 75 years old, both sexes

* Grade 1 hypertension of more
* Treated or not
* Whatever the control of BP
* Under primary of secondary prevention (more than 3 months stroke or myocard infarctus (MI), or stable angina or peripheral artery disease) PLUS at least 3 CV risk factors according to ESH-ESC 2007 guidelines or metabolic syndrome associating at least 2 of the following criteria

* SBP/DBP over 130/85 mmHg
* HDL-C \<1.0 mmol/l (0,4 g/l) (M) or \< 1.2 mmol/l (0,46 g/l) (F)
* Triglycerides \>1,7 mmol/l (\>1,5 g/l)
* Fasting blood glucose 5,6 - 6,9 mmol/l (1,02-1,25 g/l)
* Waist circumference \> 102 cm (M) ou 88 cm (F) or Type 2 diabetes or Target organ damage, according to the definition of the ESH-ESC Guidelines for the Management of Hypertension or CV disease or chronic kidney disease
2. SBP \> 180 mmHg and/or DBP \> 110 mmHg
3. SBP \> 160 mmHg AND DBP \< 70 mmHg

Exclusion Criteria

* Patients with ABPM or self-measurement normal without treatment (\<130 mmHg and 80 in the ABPM 24 or \<135 and 85 mmHg or daytime ABPM self-measurement of blood pressure)
* Patients with secondary hypertension (renal artery stenosis, pheochromocytoma, or hypermineralocortisism)
* Patients with hypertension secondary to diabetic nephropathy
* Patients aged under 55 or over 75 years,
* Low-risk CV patients
* Patients with severe chronic renal impairment creatinine clearance (MDRD) \<30ml / min / 1.73m2
* Patients with type I diabetes
* Patients with severe disease threatening the vital prognosis in the short and medium terms
* Patients who previously experienced a painful gynecomastia under spironolactone
* Patients with alcohol dependence or excessive consumption alcoholic beverages (at the judgement of the investigator)
* patients with accident history neurovascular, coronary insufficiency (coronary bypass surgery or percutaneous coronary intervention) not older than 3 month
* Patients with a history of acute heart failure or having open failure heart (NYHA class III-IV)
* Patients with unstable angina
* Auricular Fibrillation (AF) less than 6 months ago
* Patients with aortic stent
* Patients with known aneurysms of the abdominal aorta
* Patients with atrioventricular block second or third degree without pacemaker
* Patients having received organ transplant or placed on a waiting list for transplantation
* Patients with severe chronic inflammatory disease (rheumatoid arthritis; lupus; scleroderma ...)
* Patients with severe chronic infectious disease
* Patients who have had an MI less than 3 months ago
* Patients with stroke there are less than 3 months ago
* Patients with progression of peripheral arterial disease
* Patient whose pregnancy is known or which has no effective contraception if is of childbearing age, or if she is breastfeeding
* Patients who have expressed their opposition to participate in the protocol or have an inability to understand or follow the protocol
* The patients geographically too far from the place of investigation
* Patients already participating in other drug research protocol or Interventional

Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No